Heterogeneous treatment effects of GLP‐1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real‐world target trial emulation
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a decreased risk of Alzheimer's disease and related dementias (ADRD), while the protective association varied across subgroups defined by cardiovascular disease (CVD), cerebrovascular disease (CeVD), and chronic kidney disease (CKD). Similarly, sodium-glucose cotransporter-2 inhibitors (SGLT2is) were associated with a decreased risk of ADRD, with the protective association varying among subgroups defined by CVD, CeVD, and Hispanic ethnicity. There was no difference between GLP-1RAs and SGLT2is in the risk of ADRD.
Authors
- Pareeta Kotecha (ORCID: https://orcid.org/0009-0009-4864-9662)
- William T. Donahoo (ORCID: https://orcid.org/0000-0002-2126-860X)
- Jiang Bian (ORCID: https://orcid.org/0000-0002-2238-5429)
- Yao An Lee (ORCID: https://orcid.org/0009-0008-3971-4242)
- Jingchuan Guo (ORCID: https://orcid.org/0000-0001-9799-2592)
- Mikael Svensson (ORCID: https://orcid.org/0000-0003-1179-7003)
- Huilin Tang (ORCID: https://orcid.org/0000-0002-5814-6657)
- Steven T. DeKosky (ORCID: https://orcid.org/0000-0003-3743-2758)
Institutions
- Center for Drug Evaluation and Research (US)
- University of Florida Health (US)
- University of Florida (US)
- Florida College (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1002/alz.70313
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases